ArticleBlood2015
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.
Article in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01471067 (Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies), which is not on this map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
Who cites it
66 citing papers in PubMed, 131 citations in OpenAlex.
- Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders.Blood advances · 2020Trial
- Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study.The Lancet. Haematology · 2018Trial
- Factors Associated with Long-Term Risk of Relapse after Unrelated Cord Blood Transplantation in Children with Acute Lymphoblastic Leukemia in Remission.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Trial
- Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017Trial
- Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft.Cell stem cell · 2016Trial
- Fucosylation enhances CD34⁺ hematopoietic stem cell homing and longevity via E-selectin-mediated adhesion and signaling.BMC cancer · 2026Article
- Structure, function, and implications of fucosyltransferases in health and disease.Nature communications · 2025Review
- Ex Vivo Expansion of Cord Blood Hematopoietic Stem and Progenitor Cells.Methods in molecular biology (Clifton, N.J.) · 2025Article
- α1,3-fucosylation treatment improves cord blood CD34 negative hematopoietic stem cell navigation.iScience · 2024Article
- Effect of different timings of umbilical cord clamping on the level of CD34Scientific reports · 2023Article
- Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.Transplantation and cellular therapy · 2023Article
- Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future.Stem cells translational medicine · 2023Article
- The quest for the holy grail: overcoming challenges in expanding human hematopoietic stem cells for clinical use.Stem cell investigation · 2023Review
- Therapeutic Perspectives for the Clinical Application of Umbilical Cord Hematopoietic and Mesenchymal Stem Cells: Overcoming Complications Arising After Allogeneic Hematopoietic Stem Cell Transplantation.Advances in experimental medicine and biology · 2023Review
- Clinical Progress and Preclinical Insights Into Umbilical Cord Blood Transplantation Improvement.Stem cells translational medicine · 2022Review
- Refining the migration and engraftment of short-term and long-term HSCs by enhancing homing-specific adhesion mechanisms.Blood advances · 2022Article
- Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study.Bone marrow transplantation · 2022Article
- Fucosylation Promotes Cytolytic Function and Accumulation of NK Cells in B Cell Lymphoma.Frontiers in immunology · 2022Article
- Article
- Effect of Small Molecule onFrontiers in cell and developmental biology · 2021Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
41 authors at 5 institutions in 1 country.
Funding
Abstract
Delayed engraftment is a major limitation of cord blood transplantation (CBT), due in part to a defect in the cord blood (CB) cells' ability to home to the bone marrow. Because this defect appears related to low levels of fucosylation of cell surface molecules that are responsible for binding to P- and E-selectins constitutively expressed by the marrow microvasculature, and thus for marrow homing, we conducted a first-in-humans clinical trial to correct this deficiency. Patients with high-risk hematologic malignancies received myeloablative therapy followed by transplantation with 2 CB units, one of which was treated ex vivo for 30 minutes with the enzyme fucosyltransferase-VI and guanosine diphosphate fucose to enhance the interaction of CD34(+) stem and early progenitor cells with microvessels. The results of enforced fucosylation for 22 patients enrolled in the trial were then compared with those for 31 historical controls who had undergone double unmanipulated CBT. The median time to neutrophil engraftment was 17 days (range, 12-34 days) compared with 26 days (range, 11-48 days) for controls (P = .0023). Platelet engraftment was also improved: median was 35 days (range, 18-100 days) compared with 45 days (range, 27-120 days) for controls (P = .0520). These findings support ex vivo fucosylation of multipotent CD34(+) CB cells as a clinically feasible means to improve engraftment efficiency in the double CBT setting. The trial is registered to www.clinicaltrials.gov as #NCT01471067.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.